Rossari Biotech (ROSSARI) Q4 24/25 earnings summary

Executive summary

• FY 2025 delivered 13.6% revenue growth to INR 2,080 crores, with stable profitability and strong export momentum, supported by a diversified business model and R&D focus.

• HPPC segment led growth, with TSC and AHN also contributing positively; global presence expanded to over 70 countries.

• Continued investments in capacity expansion, strategic acquisitions, and innovation to support future growth.

• Audited financials for FY 2025 were approved with an unmodified opinion from statutory auditors.

• Final dividend of INR 0.5 per share recommended for FY 2025.

Financial highlights

• FY 2025 consolidated revenue reached INR 2,080.3 crores, up 13.6% YoY; EBITDA was INR 265.1 crores, up 6.1% YoY, with a 12.7% margin.

• Q4 FY 2025 revenue grew 22.6% YoY to INR 579.6 crores; EBITDA up 9.3% YoY to INR 69.5 crores.

• PAT for FY 2025 was INR 136.4 crores, up 4.4% YoY, with a PAT margin of 6.6%; diluted EPS at INR 24.6.

• Institutional and B2C business grew 67% YoY to INR 299 crores.

• Net cash from operating activities was INR 137.4 crores; major investments in property, plant, and equipment totaled INR 158.5 crores.

Outlook and guidance

• Management expects mid-teens overall revenue growth in FY 2026, with HPPC targeting low double-digit to mid-teens growth.

• Margin improvement anticipated as new businesses scale and operating leverage builds; FY 2027 projected as a strong year with new capacities online.

• Capacity addition aligns with market demand forecasts and aims to enhance competitiveness in domestic and export markets.